Sumitomo Pharma Oncology Receives Orphan Drug Designation for DSP-5336, an Investigational Menin and Mixed-Lineage Leukemia Binding Protein for Treatment of Acute Myeloid Leukemia
The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for DSP-5336.
